Review After SenesTech On-Site Factory Tour

By Ben Rabizadeh
Tuesday, December 16, 2025 2:42 PM EST


As part of his research into the company for his recent article, SenesTech's 43% Revenue Surge That Nobody's Talking About, TalkMarkets author Mark Hake visited SenesTech's (SNES) manufacturing facility. In this interview, he provides a firsthand assessment of the company’s operations, product differentiation, and business model.

The discussion explores how SenesTech’s Evolve rodent birth control product creates recurring revenue through population suppression rather than extermination. Insights from management conversations highlight production scalability, international growth opportunities, and the company’s cash runway. The analysis also outlines key risks and the milestones required for SenesTech to reach sustainable cash flow.

Watch the full interview with Mark Hake — the discussion begins around the 16:30 mark.
 

Related Articles:
SenesTech's 43% Revenue Surge That Nobody's Talking About
SenesTech Remains Undervalued With Increasing Revenues And Global Product Distribution
SenesTech's Big Play On Small Pests
SenesTech: A Little-Known Biotech Company Worthy Of Attention

Disclaimer: StoryTrading is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker, or Financial Planner. See  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Old Time Investor • 3 hours ago • Member's comment
Mark Hake During the factory tour, what did management say about their plans to scale production and meet growing demand — especially internationally — and what risks did they identify that might impact those plans?